thalidomide has been researched along with Transfusion Reaction in 4 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Transfusion Reaction: Complications of BLOOD TRANSFUSION. Included adverse reactions are common allergic and febrile reactions; hemolytic (delayed and acute) reactions; and other non-hemolytic adverse reactions such as infections and adverse immune reactions related to immunocompatibility.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hydroxyurea (HU) has demonstrated promising outcomes; additionally, thalidomide has also shown improvement in hemoglobin (Hb) levels for patients with β-thalassemia in some studies." | 1.72 | Evaluation of the combination therapy of hydroxyurea and thalidomide in β-thalassemia. ( Adil, SO; Ansari, AH; Ansari, I; Ansari, SH; Ansari, UH; Farooq, F; Hussain, Z; Khawaja, S; Masqati, NU; Sattar, A; Wasim, M; Zohaib, M, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ansari, SH | 1 |
| Ansari, I | 1 |
| Wasim, M | 1 |
| Sattar, A | 1 |
| Khawaja, S | 1 |
| Zohaib, M | 1 |
| Hussain, Z | 1 |
| Adil, SO | 1 |
| Ansari, AH | 1 |
| Ansari, UH | 1 |
| Farooq, F | 1 |
| Masqati, NU | 1 |
| Le Bras, F | 1 |
| Sebert, M | 1 |
| Kelaidi, C | 1 |
| Lamy, T | 1 |
| Dreyfus, F | 1 |
| Delaunay, J | 1 |
| Banos, A | 1 |
| Blanc, M | 1 |
| Vey, N | 1 |
| Schmidt, A | 1 |
| Visanica, S | 1 |
| Eclache, V | 1 |
| Turlure, P | 1 |
| Beyne-Rauzy, O | 1 |
| Guerci, A | 1 |
| Delmer, A | 1 |
| de Botton, S | 1 |
| Rea, D | 1 |
| Fenaux, P | 1 |
| Adès, L | 1 |
| Tiu, RV | 1 |
| Sekeres, MA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Combination of Hydroxyurea and Low-dose Thalidomide on Hemoglobin Synthesis in Thalassemia Patients[NCT05132270] | Phase 2/Phase 3 | 135 participants (Actual) | Interventional | 2020-01-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 other studies available for thalidomide and Transfusion Reaction
| Article | Year |
|---|---|
Evaluation of the combination therapy of hydroxyurea and thalidomide in β-thalassemia.
Topics: beta-Thalassemia; Blood Transfusion; Child; Combined Modality Therapy; Female; Humans; Hydroxyurea; | 2022 |
Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion--the GFM experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair | 2011 |
Lenalidomide in del 5q MDS: responses and side effects revisited.
Topics: Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide | 2011 |
Lenalidomide (Revlimid) for anemia of myelodysplastic syndrome.
Topics: Anemia; Chromosome Deletion; Chromosomes, Human, Pair 5; Contraindications; Female; Humans; Lenalido | 2006 |